Dozee has unveiled a study demonstrating the effectiveness of its AI-powered Early Warning System (EWS), which can predict patient deterioration up to 16 hours ahead of time.
Read MoreAt the 9th edition of CAHOTECH 2024, Dr. Vijay Agarwal, President of the Consortium of Accredited Healthcare Organizations (CAHO), announced several key initiatives aimed at advancing health technology and infection control practices in India.
Read MoreAt the 9th edition of CAHOTECH 2024, Dr Vijay Agarwal, President of the Consortium of Accredited Healthcare Organisations (CAHO), made two key announcements.
Read MoreAt the 9th edition of CAHOTECH 2024, Karnataka's Minister for Health & Family Welfare, Dinesh Gundu Rao, delivered a forward-looking address, emphasising the potential of technology in healthcare.
Read MoreAt the 9th edition of CAHOTECH, Dr. Devi Shetty, founder of Narayana Health, shared insights into the two-decade journey of building their digital healthcare platform, Athma.
Read MoreThe 9th edition of CAHOTECH, at the J.N. Tata Auditorium in Bangalore, brought together leaders and innovators from healthcare and technology sectors. The theme, "Redefining Healthcare: Technology as the Catalyst for Change," sets the stage for a day of insightful discussions aimed at accelerating innovation in healthcare.
Read MoreThe CAHO Masterclass for Startups, taking place on 25 October 2024 at the J.N. Tata Auditorium, will provide a comprehensive roadmap for healthcare entrepreneurs looking to bring their innovations to market.
Read MoreThe CAHOTECH 2024 Pitch Fest, happening today, promises to be an exciting platform for healthcare startups and innovators to present their groundbreaking solutions.
Read MoreCorneal blindness is rising sharply in India, with an estimated 20,000 to 25,000 new cases annually. This adds to the existing 12 lakh cases, making corneal blindness one of the major contributors to vision loss, accounting for 7.5 per cent of the total blindness burden in the country.
Read MoreThe UK’s Medicines and Healthcare products Regulatory Agency has approved Eli Lilly's new treatment for early-stage Alzheimer’s disease, donanemab, marketed under the brand name Kisunla.
Read More